Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. (Q37098796)
Jump to navigation
Jump to search
scientific article published on August 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. |
scientific article published on August 2008 |
Statements
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer (English)
Tadas Vasaitis
Aashvini Belosay
Adam Schayowitz
Aakanksha Khandelwal
Pankaj Chopra
Lalji K Gediya
Zhiyong Guo
Hong-Bin Fang
Angela M H Brodie
1 August 2008
1 reference
1 reference
1 reference
1 reference